Fulgent Genetics Inc (FLGT)vsNatera Inc (NTRA)
FLGT
Fulgent Genetics Inc
$18.14
-2.99%
HEALTHCARE · Cap: $543.87M
NTRA
Natera Inc
$215.31
-3.06%
HEALTHCARE · Cap: $30.37B
Smart Verdict
WallStSmart Research — data-driven comparison
Natera Inc generates 681% more annual revenue ($2.50B vs $320.35M). NTRA leads profitability with a -9.1% profit margin vs -23.0%. FLGT earns a higher WallStSmart Score of 40/100 (D).
FLGT
Hold40
out of 100
Grade: D
NTRA
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+54.8%
Fair Value
$50.88
Current Price
$18.14
$32.74 discount
Intrinsic value data unavailable for NTRA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Revenue surging 38.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Smaller company, higher risk/reward
ROE of -7.0% — below average capital efficiency
Revenue declined 3.2%
Earnings declined 98.6%
Trading at 17.3x book value
0.0% earnings growth
Weak financial health signals
ROE of -12.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : FLGT
The strongest argument for FLGT centers on Price/Book, Debt/Equity, Altman Z-Score. PEG of 1.32 suggests the stock is reasonably priced for its growth.
Bull Case : NTRA
The strongest argument for NTRA centers on Revenue Growth, Debt/Equity. Revenue growth of 38.8% demonstrates continued momentum.
Bear Case : FLGT
The primary concerns for FLGT are Market Cap, Return on Equity, Revenue Growth.
Bear Case : NTRA
The primary concerns for NTRA are Price/Book, EPS Growth, Piotroski F-Score.
Key Dynamics to Monitor
FLGT profiles as a turnaround stock while NTRA is a hypergrowth play — different risk/reward profiles.
NTRA carries more volatility with a beta of 1.54 — expect wider price swings.
NTRA is growing revenue faster at 38.8% — sustainability is the question.
NTRA generates stronger free cash flow (18M), providing more financial flexibility.
Bottom Line
FLGT scores higher overall (40/100 vs 31/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Fulgent Genetics Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Fulgent Genetics, Inc., provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. The company is headquartered in Temple City, California.
Natera Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?